Epilepsy Surgery
Epilepsy Surgery
What Do You Need to Know?
- Any patient who has failed two appropriately chosen, tolerated ASMs (mono- or combination) should be referred to a comprehensive epilepsy center for surgical evaluation (ILAE 2010 drug-resistant epilepsy definition; frequently tested board concept). Up to 30–40% of epilepsy patients meet criteria.
- ATL is the most common and best-studied epilepsy surgery; 60–70% Engel I for mTLE with hippocampal sclerosis at 1 year
- RCT evidence: Wiebe 2001 = 58% vs. 8% surgery vs. medical; ERSET = 73% vs. 0% — among the largest treatment effects in neurology
- SAH achieves 55–65% Engel I with better cognitive preservation; LITT/SLAH achieves 55–60% (SLATE trial: 58%) with shortest recovery
- Lesionectomy outcomes depend on pathology: low-grade tumors 75–90% > cavernomas 70–80% > FCD II 50–70% > HS 60–70% > MRI-negative 30–45%
- Corpus callosotomy: palliative for drop attacks (tonic/atonic) in LGS; eliminates drops in 55%; anterior 2/3 first
- Hemispherotomy: 73% seizure-free in children; indications = Rasmussen, hemimegalencephaly, perinatal stroke, Sturge-Weber
- Long-term: 66% maintain seizure freedom at >5 years; 22–37% recurrence beyond 10 years; ~50% achieve ASM freedom after successful surgery
🚩 Don’t Miss — Test-Day Priorities
- DRE trigger: failure of 2 appropriately chosen, tolerated ASMs (ILAE 2010) → refer to comprehensive epilepsy center; affects 30–40% of epilepsy patients
- ATL resection limits: dominant 3.5–4.5 cm, nondominant 5–6 cm from temporal pole; resects amygdala + hippocampus + parahippocampal gyrus
- ATL complications: superior quadrantanopia (~18%, Meyer loop), verbal memory decline (~44% dominant ATL), naming decline (34% dominant)
- Wiebe 2001 NEJM RCT: ATL 58% vs medical 8% seizure-free at 1 yr — NNT = 2, largest treatment effect in neurology
- LITT for MTLE-HS: SLATE trial 58% Engel I; better neuropsych outcomes than ATL; outpatient/short stay; ideal for mesial sclerosis, hypothalamic hamartoma, deep cavernoma
- Hemispherotomy > hemispherectomy: disconnection (not removal) → 73% seizure-free in children; indications = Rasmussen, hemimegalencephaly, perinatal MCA stroke, Sturge-Weber
- Corpus callosotomy: palliative for drop attacks (tonic/atonic) in LGS/Dravet; eliminates drops in 55–80%; anterior 2/3 first to avoid disconnection syndrome
- RNS (NeuroPace): bilateral mesial temporal foci, eloquent cortex, multifocal — closed-loop; median ≥70% seizure reduction at 9 yr; benefit accumulates over years
- VNS: open-loop palliative; ~50% reduction in ~50% of patients (“50/50 rule”); hoarseness/cough/dyspnea on stimulation
- SANTE / ANT-DBS: FDA-approved 2018 for focal DRE; bilateral anterior thalamic nucleus; centromedian targeted for generalized epilepsy
- Histopathology hierarchy: low-grade tumor (75–90%) > cavernoma (70–80%) > HS (60–70%) > FCD IIb (50–70%) > MRI-negative (30–45%)
- Pediatric: earlier surgery → better cognitive trajectory; young brain plasticity preserves motor function post-hemispherotomy
🔍 Buzzwords & Pathognomonic FindingsProcedure · Outcomes / histopathology · Complications
Procedure indications
- MTLE with hippocampal sclerosis → ATL (mainstay) or SelAH or LITT
- Drop attacks (tonic/atonic) in LGS / Dravet → corpus callosotomy (anterior 2/3)
- Rasmussen encephalitis / hemimegalencephaly / Sturge-Weber / large perinatal MCA stroke → hemispherotomy
- Hypothalamic hamartoma / deep cavernoma / periventricular nodular heterotopia → LITT (MR-guided laser ablation)
- Seizure focus in eloquent cortex (motor/language) → multiple subpial transection (MST) or RNS
- Bilateral mesial temporal / multifocal DRE → RNS (NeuroPace, closed-loop)
- Palliative when resection not possible → VNS or ANT-DBS (SANTE)
- Focal cortical dysplasia / tumor / encephalomalacia (extra-temporal) → extra-temporal cortical resection / lesionectomy
Outcomes / histopathology
- MTLE-HS (Wieser type 1a–c) → best outcome — 60–70% Engel I after ATL
- FCD type IIb (transmantle sign, balloon cells) → 50–70% Engel I if completely resected
- Low-grade glioma / DNET / ganglioglioma → 75–90% Engel I (best lesional outcome)
- Cavernoma → 70–80% Engel I after lesionectomy + hemosiderin rim
- MRI-negative / non-lesional focal epilepsy → 30–45% Engel I (worst outcome)
- SelAH vs ATL → 55–65% Engel I, better naming/verbal memory preservation
- LITT (SLATE trial) → 58% Engel I for MTLE-HS, superior neuropsych profile
- Pediatric hemispherotomy → 73% seizure-free; preserved motor function via contralateral plasticity
Complications
- Superior quadrantanopia (“pie in the sky”) → ATL (Meyer loop in optic radiation, ~18%)
- Verbal memory decline (~44%) / naming decline (34%) → dominant (left) ATL
- Disconnection syndrome (alien hand, mutism) → complete corpus callosotomy (avoided by anterior 2/3 first)
- Hoarseness, cough, dyspnea on stimulation → VNS (left vagus stimulation)
- Hemiparesis / hemianopia (permanent major deficit ~4.7%) → any resective epilepsy surgery
- De novo depression / anxiety (“burden of normality”) → post-ATL (10–20%)
- Transient CN III/IV palsy from retraction → ATL / SelAH (~2%)
- Hydrocephalus / aseptic meningitis → hemispherotomy
Drug-Resistant Epilepsy (DRE) Definition
- ILAE 2010 definition (Kwan et al., Epilepsia 2010): DRE = failure of two appropriately chosen, tolerated, and used ASM schedules — whether as monotherapy or in combination — to achieve sustained seizure freedom
- DRE is the gateway to surgical referral
- Up to 30–40% of epilepsy patients have DRE
💎 Board Pearl
ILAE 2010 DRE = failure of 2 appropriately chosen, tolerated, and used ASMs (mono- or combination) to achieve sustained seizure freedom. DRE triggers surgical referral; 30–40% of epilepsy patients meet criteria.
Anterior Temporal Lobectomy (ATL)
Overview
- Most common and best-studied epilepsy surgery worldwide
- Standard procedure for mesial temporal lobe epilepsy (mTLE) with hippocampal sclerosis
- Resects anterior temporal neocortex + mesial structures (amygdala, hippocampus, parahippocampal gyrus)
Resection Extent
- Dominant hemisphere: 3.5–4.5 cm from temporal pole
- Nondominant hemisphere: 5–6 cm from temporal pole
- Intraoperative ECoG may guide additional resection beyond standard limits
Outcomes
- Engel I at 1 year: 60–70% for mTLE with HS; 40–55% without HS
- Wiebe 2001 (NEJM): RCT — surgery 58% vs. medical 8% seizure-free at 1 year
- ERSET 2012 (JAMA): n=38 (terminated early for slow accrual); 11/15 (73%) surgical vs. 0/23 (0%) medical seizure-free during year 2
- NNT = 2 (Wiebe; ARR = 0.58 − 0.08 = 0.50) — one of the largest treatment effects in clinical neurology
Complications
| Complication | Incidence | Notes |
|---|---|---|
| Superior quadrantanopia | ~18% | Disruption of Meyer loop (optic radiation) |
| Verbal memory decline | ~44% clinically meaningful decline after dominant ATL (Sherman 2011) | Higher risk with strong preoperative memory, late onset, normal contralateral hippocampus |
| Naming decline | 34% (dominant side) | Due to lateral temporal neocortex resection |
| De novo psychiatric symptoms | 10–20% | Depression, anxiety; “burden of normality” |
| Cranial neuropathies | ~2% | Transient CN III/IV from retraction |
| Major permanent deficits | 4.7% | Hemiparesis, hemianopia |
| Mortality | <0.6% | All epilepsy surgeries |
💎 Board Pearl
Dominant ATL resection limit = 3.5–4.5 cm; nondominant = 5–6 cm. Left ATL carries the highest risk of verbal memory (44%) and naming (34%) decline — boards test cognitive risk stratification by laterality.
Selective Amygdalohippocampectomy (SAH)
Key Points
- Targets only mesial structures (amygdala, hippocampus, parahippocampal gyrus) while preserving lateral temporal neocortex
- Engel I: 55–65% — may be slightly lower than standard ATL
- Cognitive advantage: better naming and verbal memory preservation, especially with transsylvian approach
Surgical Approaches
| Approach | Access Route | Key Risk |
|---|---|---|
| Transsylvian | Through sylvian fissure | MCA branch injury; technically demanding |
| Transcortical | Through middle/inferior temporal gyrus | Visual field defect (Meyer loop disruption) |
| Subtemporal | Under temporal lobe | Vein of Labbé injury; retraction injury |
- Less tissue removed than ATL — may have slightly lower seizure-free rates
- Best for patients where cognitive preservation is a priority, especially dominant hemisphere
LITT / SLAH (Laser Interstitial Thermal Therapy)
Overview
- MRI-guided stereotactic laser ablation via 3.2 mm burr hole
- Hospital stay: 1–2 days; return to work: 1–2 weeks
- Real-time MRI thermometry monitors ablation in real time
Outcomes for MTLE
- Engel I: 55–60% at 12 months
- SLATE trial (prospective multicenter, 114 treated): 58% Engel I at 12 months
- Lower seizure-freedom rate than ATL (60–70%) — trade-off for minimally invasive approach
Cognitive Advantages
- Better naming preservation than open ATL (spares lateral temporal neocortex)
- Better verbal memory outcomes for dominant-hemisphere surgery
- Particularly valuable for left-sided MTLE where cognitive risk is highest
Technical Keys & Pitfalls
- Most common cause of failure: incomplete hippocampal head ablation
- Target: 60–70% of hippocampus + most of amygdala
- Does NOT “burn bridges” — open ATL remains fully feasible after LITT failure
- Complications: hemorrhage ~1.5%, visual field defect 8.8%, transient CN III/IV palsy 3.1%
Hypothalamic Hamartoma
- 60–80% seizure-free with LITT in experienced centers
- First-line treatment at some centers for gelastic seizures from hypothalamic hamartoma
- Lower complication rates than open/endoscopic approaches for this deep-seated target
💎 Board Pearl
LITT incomplete hippocampal head ablation = #1 cause of failure; target 60–70% hippocampal ablation. LITT does NOT burn bridges — open ATL is still feasible after failed LITT. For hypothalamic hamartoma + gelastic seizures, LITT is first-line at many centers.
Lesionectomy Outcomes by Pathology
| Pathology | Engel I Rate | Key Considerations |
|---|---|---|
| Low-grade tumors (ganglioglioma, DNET) | 75–90% | Best outcomes; gross total resection is critical; may consider early surgery |
| Cavernous malformations | 70–80% | Resect surrounding hemosiderin ring; ECoG-guided resection improves outcomes |
| FCD Type II | 50–70% | Type IIb best (70–80%); complete resection often difficult; indistinct margins |
| Hippocampal sclerosis | 60–70% | Standard ATL or SAH; concordant semiology + EEG + MRI = best outcome |
| MRI-negative | 30–45% | Least favorable; requires Phase II (SEEG); advanced MRI postprocessing may reveal subtle FCD |
Predictors of Surgical Success
- Complete resection = single strongest predictor regardless of pathology
- Concordance between semiology, EEG, and MRI
- ECoG-guided extended resection for residual epileptiform activity
- Visible MRI lesion > MRI-negative for surgical planning and outcome
💎 Board Pearl
Lesionectomy outcome hierarchy: ganglioglioma/DNET (75–90%) > cavernoma (70–80%) > FCD IIb (70–80%) > HS (60–70%) > MRI-negative (30–45%). Complete resection is the #1 predictor of seizure freedom across all pathologies.
Corpus Callosotomy
Indications
- Primary indication: disabling DROP ATTACKS (tonic, atonic seizures) refractory to medical therapy
- LGS is the most common indication
- Palliative procedure — does not cure epilepsy but reduces most disabling seizure type
- Not for focal resectable epilepsy; reserved for generalized or multifocal epilepsy
Procedure
- Staged approach preferred: anterior 2/3 callosotomy first; complete callosotomy if drop attacks persist
- Complete callosotomy more effective but higher risk of disconnection syndrome
Outcomes
- Eliminates drop seizures: 55% of patients
- Complete seizure freedom: 19%
- Better outcomes with: history of infantile spasms, shorter epilepsy duration, complete callosotomy
Disconnection Syndrome
- Alien hand syndrome: hand acts independently; more common with complete callosotomy
- Split-brain effects: interhemispheric transfer deficits — naming difficulty for objects in left hand, writing/reading deficits, bimanual coordination problems
- Transient postop deficits: leg weakness, akinesia, mutism from medial frontal retraction — usually resolve in days to weeks
- Risk higher with complete callosotomy → supports staged approach
💎 Board Pearl
Corpus callosotomy = the board answer for disabling drop attacks in LGS. Staged approach: anterior 2/3 first. Alien hand syndrome = classic board complication of complete callosotomy. 55% drop seizure elimination; only 19% achieve total seizure freedom.
Hemispherectomy / Hemispherotomy
Indications
- Rasmussen encephalitis: progressive unilateral encephalitis + epilepsia partialis continua — hemispherectomy is the definitive treatment
- Hemimegalencephaly: unilateral hemispheric enlargement with drug-resistant epilepsy
- Perinatal stroke: large unilateral infarction with resultant epilepsy
- Sturge-Weber syndrome: hemispheric leptomeningeal angiomatosis
- Candidates typically have preexisting contralateral hemiparesis
Procedure Types
- Anatomic hemispherectomy: complete hemisphere removal — historical; associated with superficial hemosiderosis and hydrocephalus
- Hemispherotomy (functional disconnection): preferred modern technique — disconnects hemisphere while preserving most cortex
- Techniques: vertical parasagittal, periinsular, endoscopic-assisted
Outcomes
- 73% seizure-free in children at last follow-up
- Better outcomes in younger children (greater neuroplasticity for functional reorganization)
- Adults have comparable Engel I rates when appropriately selected
Expected Deficits
- Contralateral hemiparesis: most patients already have preoperative hemiparesis; upper extremity typically more affected
- Homonymous hemianopia: expected and accepted
- Language: children with early-onset hemispheric pathology often have significant language reorganization to contralateral hemisphere
- Complications: hydrocephalus requiring shunt 10–20%, hemorrhage, aseptic meningitis
💎 Board Pearl
Rasmussen encephalitis = progressive unilateral hemispheric disease + epilepsia partialis continua → hemispherotomy is definitive treatment. Hemispherotomy (functional disconnection) is preferred over anatomic hemispherectomy. 73% seizure-free in children.
Extratemporal Resections
Frontal Lobe Epilepsy Surgery
- Engel I at 1 year: 30–50%
- Engel I at 5 years: only 28% — significantly worse than temporal resections
- Challenges: large epileptogenic zones, rapid seizure propagation, proximity to eloquent cortex, frequent MRI-negative cases
- SEEG is often required for bilateral frontal exploration
Parietal and Occipital Lobe Surgery
- Limited data; variable outcomes (50–65% for lesional cases)
- Parietal: risk of sensory deficits, apraxia, Gerstmann syndrome (dominant side)
- Occipital: contralateral hemianopia is expected if primary visual cortex is resected
Key Principle
- FCD IIb = best extratemporal surgical outcome (well-defined margins, transmantle sign on MRI)
- MRI-negative extratemporal epilepsy has the lowest surgical success rates
Long-Term Outcomes
| Measure | Temporal Resection | Frontal Resection |
|---|---|---|
| Seizure-free at >5 years | 66% | 28% |
| Recurrence at >10 years | 22–37% | Higher |
| Pediatric at 10 years | 61% seizure-free (combined surgical types) | |
Late Recurrence
- Recurrence after initial 2-year seizure freedom occurs in 22–37% beyond 10 years
- Recurrent seizures are typically less frequent and less severe than preoperatively
- Late recurrence often manageable with ASM restart or medication adjustment
- Further surgical evaluation may identify treatable residual epileptogenic zone
ASM Management Post-Surgery
Timeline
- Continue all preoperative ASMs for a minimum of 1–2 years after surgery
- Early postoperative seizures (first 1–2 weeks) = “running-down” seizures; do NOT necessarily predict surgical failure
- If seizure-free at 1–2 years: consider slow taper, one ASM at a time
ASM Withdrawal
- ~50% of patients eventually achieve complete ASM freedom after successful surgery
- Recurrence risk after complete withdrawal: 20–30%
- Predictors of safe withdrawal: Engel IA, normal postoperative EEG, lesional pathology (HS, tumor), absence of generalized discharges
- Decision must weigh medication side effects vs. recurrence risk (driving, employment, injury)
Preoperative Cognitive / Language Assessment
Wada (Intracarotid Amobarbital Procedure)
- Assesses language lateralization and memory adequacy of the contralateral hippocampus
- Invasive: requires catheter angiography
- Transient complications ~0.6%; permanent stroke ~0.05–0.1%
fMRI
- Increasingly replaces Wada for LANGUAGE lateralization
- >90% concordance with Wada in right-handers
- Concordance drops to ~70–80% in left-handers, patients with bilateral language representation, and lesional cases
When Wada Is Still Preferred
- Memory lateralization — Wada remains preferred when memory lateralization matters
- When fMRI language is atypical or inconclusive
Neuropsychological Testing
- Baseline assessment is essential for all surgical candidates
- Verbal memory deficit lateralizes to the language-dominant temporal lobe — helps confirm laterality of seizure focus
💎 Board Pearl
fMRI has replaced Wada for LANGUAGE in right-handers (>90% concordance) but Wada is still preferred for MEMORY lateralization and when fMRI language is atypical (left-handers, bilateral representation). Wada permanent stroke risk ~0.05–0.1%. Verbal memory deficit on neuropsych lateralizes to the language-dominant temporal lobe.
Comparison of Surgical Approaches for MTLE
| Feature | ATL | SAH | LITT/SLAH |
|---|---|---|---|
| Engel I at 1 year | 60–70% | 55–65% | 55–60% |
| Cranial access | Craniotomy | Craniotomy | 3.2 mm burr hole |
| Hospital stay | 3–5 days | 3–5 days | 1–2 days |
| Naming decline (dominant) | 34% | Lower than ATL | Lowest risk |
| Verbal memory decline (L) | ~44% clinically meaningful decline after dominant ATL (Sherman 2011) | Better than ATL | Best preservation |
| Visual field defect | 18% | Variable by approach | 8.8% |
| Return to activities | 4–6 weeks | 4–6 weeks | 1–2 weeks |
| Salvage after failure | Limited | ATL possible | ATL fully feasible |
Neurostimulation (VNS, RNS [NeuroPace, FDA-approved 2013], ANT-DBS [SANTE trial, FDA-approved 2018]) is covered in a separate topic.
💎 Board Pearl
- ATL for mTLE-HS: 60–70% Engel I — best-studied epilepsy surgery; Wiebe 2001 = 58% vs. 8%; ERSET = 73% vs. 0%
- Dominant ATL resection limit: 3.5–4.5 cm; nondominant = 5–6 cm from temporal pole
- Left ATL cognitive risk: clinically meaningful verbal memory decline ~44% after dominant ATL (Sherman 2011), naming decline 34% — highest among all approaches
- LITT failure: incomplete hippocampal head ablation is #1 cause; target 60–70% hippocampal ablation; does NOT burn bridges for future ATL
- Corpus callosotomy = drop attacks in LGS: staged anterior 2/3 first; alien hand syndrome = classic board complication of complete callosotomy
- Rasmussen encephalitis: hemispherotomy is the definitive treatment; do not delay for immunotherapy to “cure” the disease
- Complete lesion resection is the single strongest predictor of seizure freedom regardless of pathology; FCD IIb = best extratemporal outcome
Clinical Pearls
- De novo psychiatric symptoms occur in 10–20% postoperatively, even in seizure-free patients — “burden of normality” is real; preoperative psychiatric screening and postoperative follow-up at 3, 6, and 12 months are essential
- ASM withdrawal after surgery: wait a minimum of 1–2 years if seizure-free, then taper one ASM at a time; ~50% eventually achieve complete ASM freedom; predictors = Engel IA, normal postop EEG, lesional pathology
- Surgical referral timing: despite Level 1 evidence, average time from epilepsy onset to surgery remains >20 years; ILAE recommends referral after failure of 2 appropriate ASMs — early surgery improves cognitive and QOL outcomes
References
- Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311–318.
- Engel J Jr, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial (ERSET). JAMA. 2012;307(9):922–930.
- Friedman D, Engel J. Surgical treatments, devices, and nonmedical management of epilepsy. Continuum (Minneap Minn). 2025;31(1):165–186.
- Téllez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain. 2005;128(Pt 5):1188–1198.
- de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse. Lancet. 2011;378(9800):1388–1395.
- Josephson CB, Dykeman J, Fiest KM, et al. Systematic review and meta-analysis of standard vs selective temporal lobe epilepsy surgery. Neurology. 2013;80(18):1669–1676.
- Kohlhase K, Zöllner JP, Tandon N, Strzelczyk A, Rosenow F. Comparison of minimally invasive and traditional surgical approaches for refractory mesial temporal lobe epilepsy. Epilepsia. 2021;62(4):831–845.
- Chan AY, Rolston JD, Lee B, Vadera S, Englot DJ. Rates and predictors of seizure outcome after corpus callosotomy: a meta-analysis. J Neurosurg. 2018;130(4):1193–1202.
- Griessenauer CJ, Salam S, Hendrix P, et al. Hemispherectomy for treatment of refractory epilepsy in the pediatric age group: a systematic review. J Neurosurg Pediatr. 2015;15(1):34–44.
- Hader WJ, Tellez-Zenteno J, Metcalfe A, et al. Complications of epilepsy surgery: a systematic review of focal surgical resections and invasive EEG monitoring. Epilepsia. 2013;54(5):840–847.
- Du VX, Gandhi SV, Rekate HL, Mehta AD. Laser interstitial thermal therapy: a first line treatment for seizures due to hypothalamic hamartoma? Epilepsia. 2017;58(Suppl 2):77–84.
- Sherman EMS, Wiebe S, Fay-McClymont TB, et al. Neuropsychological outcomes after epilepsy surgery: systematic review and pooled estimates. Epilepsia. 2011;52(5):857–869.
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.